Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting  

作　　者：Ruogu Qi Shanshan Wang Jiayi Yu Tianming Lu Zhiqiang Bi Weibo Liu Yuanyuan Guo Yong Bian Jianliang Shen Xuesong Zhang Wenhao Hu 

机构地区：[1]School of Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China [2]Laboratory Animal Center,Nanjing University of Chinese Medicine,Nanjing 210023,China [3]Key Laboratory of Carcinogenesis and Translational Research,Ministry of Education/Beijing,Department of Radiation Oncology,Beijing Cancer Hospital,Beijing 100142,China [4]Department of Orthopedics,The Fourth Medical Center,The Chinese People’s Liberation Army General Hospital,Beijing 100853,China [5]State Key Laboratory of Ophthalmology,Optometry and Vision Science,School of Biomedical Engineering,Wenzhou Medical University,Wenzhou 325027,China

出　　处：《Engineering》2024年第5期178-192,共15页工程（英文）

基　　金：supported by the National Natural Science Foundation of China(52073145 and 82004081);the Jiangsu Talent Professor Program,Jiangsu Innovation Project of Graduate Student(KYCX23-2192);the National Natural Science Foundation of Nanjing University of Chinese Medicine(NZY82004081);the Special Grants of China Postdoctoral Science Foundation(2021T140792).

摘　　要：Multiple myeloma(MM)is the second most prevalent hematological malignancy.Current MM treatment strategies are hampered by systemic toxicity and suboptimal therapeutic efficacy.This study addressed these limitations through the development of a potent MM-targeting chemotherapy strategy,which capitalized on the high binding affinity of alendronate for hydroxyapatite in the bone matrix and the homologous targeting of myeloma cell membranes,termed [e-mail] results from our investigations highlight the considerable bone affinity of T-PB@M,both in vitro and in vivo.Additionally,this material demonstrated a capability for drug release triggered by low pH conditions.Moreover,T-PB@M induced the generation of reactive oxygen species and triggered cell apoptosis through the poly(ADP-ribose)polymerase 1(PARP1)-Caspase-3-B-cell lymphoma-2(Bcl-2)pathway in MM cells.Notably,T-PB@M preferentially targeted bone-involved sites,thereby circumventing systemic toxic side effects and leading to prolonged survival of MM orthotopic mice.Therefore,this designed target-MM nanocarrier presents a promising and potentially effective platform for the precise treatment of MM.

关 键 词：Multiple myeloma BORTEZOMIB Drug delivery Dual targeting Controlled release 

分 类 号：R733.3[医药卫生—肿瘤]